share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K：諾和諾德-股票回購計劃
美股sec公告 ·  07/22 11:16
Moomoo AI 已提取核心訊息
On July 22, 2024, Novo Nordisk A/S, a global healthcare leader headquartered in Denmark, reported progress on its share repurchase program. The program, which is part of a larger DKK 20 billion buyback initiative set to occur over 12 months starting February 6, 2024, saw the company repurchasing B shares amounting to DKK 2.2 billion between May 7 and August 5, 2024. Since the last update on July 15, Novo Nordisk has acquired an additional 186,967 B shares at an average price of DKK 941.45, totaling DKK 175,979,457. Overall, from the beginning of the buyback period on February 6, 2024, the company has repurchased 10,619,037 B shares at an average price of DKK 878.31 per share, amounting to DKK 9,326,780,889. These transactions have increased the company's treasury shares to 11,984,827 B shares, which is 0.3% of the share capital. Novo Nordisk's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange under the symbols 'Novo-B' and 'NVO', respectively.
On July 22, 2024, Novo Nordisk A/S, a global healthcare leader headquartered in Denmark, reported progress on its share repurchase program. The program, which is part of a larger DKK 20 billion buyback initiative set to occur over 12 months starting February 6, 2024, saw the company repurchasing B shares amounting to DKK 2.2 billion between May 7 and August 5, 2024. Since the last update on July 15, Novo Nordisk has acquired an additional 186,967 B shares at an average price of DKK 941.45, totaling DKK 175,979,457. Overall, from the beginning of the buyback period on February 6, 2024, the company has repurchased 10,619,037 B shares at an average price of DKK 878.31 per share, amounting to DKK 9,326,780,889. These transactions have increased the company's treasury shares to 11,984,827 B shares, which is 0.3% of the share capital. Novo Nordisk's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange under the symbols 'Novo-B' and 'NVO', respectively.
2024年7月22日，總部位於丹麥的全球醫療保健領導者Novo Nordisk A / S在其股票回購計劃中取得了進展。該計劃是一個更大的DKk 200億回購倡議的一部分，開始於2024年2月6日，爲期12個月，公司在2024年5月7日至8月5日期間收購了價值爲DKk 22億的B類股票。自7月15日上次更新以來，Novo Nordisk已收購了額外的1869670億股股票，平均價格爲DKk 941.45，總額爲DKk 175,979,457。總體而言，自2024年2月6日回購期開始以來，該公司已以每股DKk 878.31的平均價格回購了106190370億股股票，總額達到DKk 9,326,780,889。這些交易將公司的庫存股份增加到119848270億股，佔股本的0.3％。Novo Nordisk的股票在納斯達克哥本哈根交易所和紐約證券交易所上市，分別以“Novo-B”和“NVO”爲代碼。
2024年7月22日，總部位於丹麥的全球醫療保健領導者Novo Nordisk A / S在其股票回購計劃中取得了進展。該計劃是一個更大的DKk 200億回購倡議的一部分，開始於2024年2月6日，爲期12個月，公司在2024年5月7日至8月5日期間收購了價值爲DKk 22億的B類股票。自7月15日上次更新以來，Novo Nordisk已收購了額外的1869670億股股票，平均價格爲DKk 941.45，總額爲DKk 175,979,457。總體而言，自2024年2月6日回購期開始以來，該公司已以每股DKk 878.31的平均價格回購了106190370億股股票，總額達到DKk 9,326,780,889。這些交易將公司的庫存股份增加到119848270億股，佔股本的0.3％。Novo Nordisk的股票在納斯達克哥本哈根交易所和紐約證券交易所上市，分別以“Novo-B”和“NVO”爲代碼。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息